BioSpace News Archive

Axsome Therapeutics, Inc. announced the Company’s 2020 Annual Meeting of Stockholders will now be held in a virtual-only meeting format due to continued public health concerns resulting from the COVID-19 pandemic, government-recommended and required limits on public gatherings, and to protect the health and safety of the Company’s stockholders, directors, and employees.

STERIS plc announced that the U.S. Food and Drug Administration has issued another Emergency Use Authorization for respirator decontamination.

Centene Corporation announced that it has donated $500,000 to the National Domestic Violence Hotline, which aims to support and advocate for those affected by relationship abuse.

SMART’s G-EYE® Colonoscope, incorporating the G-EYE® Balloon Technology which helps control the endoscope’s field of view and positioning during colonoscopy, was cleared for marketing in the USA by FDA

Vanda Pharmaceuticals Inc., announced that Vanda will hold its 2020 Annual Meeting of Stockholders in a virtual-only format due to public health concerns related to the COVID-19 pandemic and to protect the health and well-being of its stockholders, directors, employees and the public.

Concert Pharmaceuticals, Inc. announced that Roger Tung, Ph.D., President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Virtual Global Healthcare Conference on June 2, 2020, at 2:00 p.m. ET.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment o

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket is scheduled to present on Tuesday, June 2, 2020, at 2:00 p.m. Eastern Time at the Jefferies Virtual Healthcare Conference A live audio webcast of the presentation wi

Primary Effectiveness and Safety Endpoints Were Met. The OCS Liver Achieved Statistical Superiority of The Primary Effectiveness Endpoint by Demonstrating Significant Reduction of Early Allograft Dysfunction (EAD) Compared to Control.

Atara Biotherapeutics, Inc. announced the presentation of additional safety and efficacy data from its ongoing Phase 1 study of ATA188 for the treatment of progressive forms of multiple sclerosis.